Alternative Investment Advisors LLC. Purchases 2,612 Shares of Geron Co. (NASDAQ:GERN)

Alternative Investment Advisors LLC. lifted its position in Geron Co. (NASDAQ:GERN) by 13.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 22,209 shares of the biopharmaceutical company’s stock after acquiring an additional 2,612 shares during the period. Alternative Investment Advisors LLC.’s holdings in Geron were worth $101,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. National Bank of Canada FI increased its holdings in shares of Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares in the last quarter. Readystate Asset Management LP bought a new stake in Geron in the 3rd quarter worth about $58,000. Rovin Capital UT ADV purchased a new position in Geron in the 3rd quarter worth about $62,000. CIBC Asset Management Inc lifted its stake in Geron by 32.7% during the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 3,805 shares during the period. Finally, Empowered Funds LLC bought a new stake in shares of Geron in the third quarter worth approximately $67,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Price Performance

Shares of GERN stock traded down $0.09 during mid-day trading on Friday, hitting $3.83. The company had a trading volume of 1,223,070 shares, compared to its average volume of 10,129,486. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The stock’s 50 day moving average price is $4.08 and its 200-day moving average price is $4.34. Geron Co. has a 52-week low of $1.64 and a 52-week high of $5.34. The company has a market capitalization of $2.32 billion, a P/E ratio of -12.25 and a beta of 0.51.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The business had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. During the same quarter in the prior year, the firm earned ($0.08) EPS. The business’s revenue was up 17138.4% on a year-over-year basis. Equities research analysts forecast that Geron Co. will post -0.25 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GERN shares. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Geron in a report on Friday. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Geron in a research note on Tuesday. Scotiabank initiated coverage on shares of Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price objective on the stock. Finally, Leerink Partners started coverage on shares of Geron in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.15.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.